Dergiler / Turkish Journal of Medical Sciences / 2015 / Cilt: 45 - Sayı: 5

Plasma 8-isoPGF2α and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease

Sayfa
1073–1077
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Although the plasma 8-isoPGF2α and serum melatonin levels in MCI were not found to be good early diagnostic markers to indicate risk of AD, results were found to support the role of oxidative stress in AD.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: F2α-isoprostane is accepted as an oxidative stress indicator and melatonin shows neuroprotective effects by antioxidative and antiamyloidogenic influences.
📊
Temel Bulgular & Veri:By measuring these in patients diagnosed with minimal cognitive impairment (MCI) and Alzheimer-type dementia, we intended to demonstrate whether the measurement of these markers contributes to early diagnosis of Alzheimer disease (AD) in the MCI stage or not.
💡
Sonuç & Katkı:Conclusion: Although the plasma 8-isoPGF2α and serum melatonin levels in MCI were not found to be good early diagnostic markers to indicate risk of AD, results were found to support the role of oxidative stress in AD.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: F2α-isoprostane is accepted as an oxidative stress indicator and melatonin shows neuroprotective effects by antioxidative and antiamyloidogenic influences. By measuring these in patients diagnosed with minimal cognitive impairment (MCI) and Alzheimer-type dementia, we intended to demonstrate whether the measurement of these markers contributes to early diagnosis of Alzheimer disease (AD) in the MCI stage or not. Materials and methods: Three groups (n = 63) were created: the AD group, MCI group, and control group. Serum melatonin levels were measured by radioimmunoassay method, and plasma total 8-isoPGF2α levels were measured by enzyme immunoassay method. Results: Significant differences were observed in the melatonin levels between the MCI group and AD group (P = 0.009), and in 8-isoPGF2α levels between the AD group and control group (P = 0.022). A negative correlation between mini-mental state examination (MMSE) scores and 8-isoPGF2α levels (r = 0.459, P < 0.001) and positive correlation between MMSE scores and melatonin levels (r = 0.317, P = 0.011) were found. Conclusion: Although the plasma 8-isoPGF2α and serum melatonin levels in MCI were not found to be good early diagnostic markers to indicate risk of AD, results were found to support the role of oxidative stress in AD.

🔖

Bu Makaleye Atıf Yap

ŞİRİN, F. B., SÜTÇÜ, R., EREN, İ., İNANLI, İ., DELİBAŞ, N., VURAL, H., KUMBUL, D. D. (2022). Plasma 8-isoPGF2α and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease. Turkish Journal of Medical Sciences, Cilt: 45 - Sayı: 5, 1073–1077. https://ajindex.com/articles/610935

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (17)

  1. Selekler K. Alzheimer hastalığının öncesi: hafif kognitif bozukluk. Hacettepe Tıp Dergisi 2004; 35: 199–206 (in Turkish)
  2. Petersen RC. Mild cognitive impairment: where are we? Alzheimer Dis Assoc Disord 2005; 19: 166–169
  3. Chertkow H. Mild cognitive impairment. Curr Opin Neurol 2002; 15: 401–407
  4. Cardinalli DP, Vigo DE, Olivar N, Vidal MF, Furio AM, Brusco LI. Therapeutic application of melatonin in mild cognitive impairment. Am J Neurodegener Dis 2012; 1: 280–291
  5. Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer’s disease. Neurobiol Aging 1997; 18: 85–88
  6. Montine TJ, Neely MD, Quinn JF, Beal F, Markesbery WR. Lipid peroxidation in aging brain and Alzheimer’s Disease. Free Radic Biol Med 2002; 33: 620–626
  7. Pratico D, Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer’s disease. Am J Med 2000; 109: 577–585
  8. Smith MA, Rottkamp C, Nunomura A, Raina AK, Perry G. Oxidative stress in Alzheimer’s disease. Biochim Biophys Acta 2000; 1502: 139–144
  9. ChristenY. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000; 71: 621–629
  10. Mariani E, Polidori MC, Cherubini A, Mecocci P. Oxidative stress in aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 827: 65–75
  11. Praticò D, Lawson JA, Rokach J, FitzGerald GA. The isoprostanes in biology and medicine. Trends Endocrinol Metab 2001; 12: 243–247
  12. Pratico D, Lawson JA, FitzGerald GA. Cyclooxygenasedependent formation of the isoprostane, 8-epi PGF2α. J Biol Chem 1995; 270: 9800–9808
  13. Reiter RJ. Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab 2003; 17: 273–285
  14. Matuszak Z, Reszka KJ, Chignell CF. Reaction of melatonin and related indoles with hydroxyl radicals: ESR and spin trapping investigations. Free Radic Biol Med 1997; 23: 367–372
  15. Pappolla MA, Chyan YJ, Poeggeler B. An assessment of the antioxidant and antiamyloidogenic properties of melatonin: implications for Alzheimer’s disease. J Neural Transm 2000; 107: 203–231
  16. Bettahi I, Pozo D, Osuna C, Reiter RJ, Acuna-Castroviejo D, Guerrero JM. Melatonin reduces nitric oxide synthase activity in rat hypothalamus. J Pineal Res 1996; 20: 205–210
  17. Liu RY, Zhou JN, van Heerikhuize J, Hofman MA, Swaab DF. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer’s disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Meta